egf-rp64k
Biologicalexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01444118)
Timeline
Indications
Mechanism of action
- Pro-epidermal growth factorImmunity, active
EGF immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- egf-rp64k
- regf-p64k
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02955290 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2016 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT01444118 | Phase 3 | Nov 1, 2011 | Bioven, University of Aberdeen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bioven | For profit | 1 | 1 | 1 | 2011 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2016 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2016 |
| University of Aberdeen | Academic/Hospital | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1